Teva Pharmaceutical Industries Limited (TLV:TEVA)
9,155.00
+264.00 (2.97%)
At close: Dec 4, 2025
TLV:TEVA Revenue
Teva Pharmaceutical Industries had revenue of $4.48B USD in the quarter ending September 30, 2025, with 3.42% growth. This brings the company's revenue in the last twelve months to $16.78B, up 0.02% year-over-year. In the year 2024, Teva Pharmaceutical Industries had annual revenue of $16.54B with 4.40% growth.
Revenue (ttm)
$16.78B
Revenue Growth
+0.02%
P/S Ratio
1.90
Revenue / Employee
$470.10K
Employees
35,686
Market Cap
105.71B ILS
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16.54B | 698.00M | 4.40% |
| Dec 31, 2023 | 15.85B | 921.00M | 6.17% |
| Dec 31, 2022 | 14.93B | -953.00M | -6.00% |
| Dec 31, 2021 | 15.88B | -781.00M | -4.69% |
| Dec 31, 2020 | 16.66B | -228.00M | -1.35% |
| Dec 31, 2019 | 16.89B | -1.38B | -7.57% |
| Dec 31, 2018 | 18.27B | -3.58B | -16.39% |
| Dec 31, 2017 | 21.85B | -50.00M | -0.23% |
| Dec 31, 2016 | 21.90B | 2.25B | 11.45% |
| Dec 31, 2015 | 19.65B | -620.00M | -3.06% |
| Dec 31, 2014 | 20.27B | -42.00M | -0.21% |
| Dec 31, 2013 | 20.31B | -3.00M | -0.01% |
| Dec 31, 2012 | 20.32B | 2.01B | 10.95% |
| Dec 31, 2011 | 18.31B | 2.19B | 13.59% |
| Dec 31, 2010 | 16.12B | 2.22B | 15.99% |
| Dec 31, 2009 | 13.90B | 2.81B | 25.39% |
| Dec 31, 2008 | 11.09B | 1.68B | 17.83% |
| Dec 31, 2007 | 9.41B | 1.00B | 11.89% |
| Dec 31, 2006 | 8.41B | 3.16B | 60.15% |
| Dec 31, 2005 | 5.25B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Danel (Adir Yeoshua) | 2.87B |
| Novolog (Pharm-Up 1966) | 1.97B |
| Ilex Medical | 915.05M |
| Kamada | 578.74M |
| SofWave Medical | 255.13M |
| InterCure | 243.12M |
| BrainsWay | 162.56M |
| Bait Bakfar | 107.78M |
Teva Pharmaceutical Industries News
- 1 day ago - Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue - 24/7 Wall street
- 2 days ago - Teva Pharmaceutical (TEVA) Receives Sector Outperform Rating from Scotiabank | TEVA Stock News - GuruFocus
- 2 days ago - Teva Pharmaceutical Industries Ltd at Citi Global Healthcare Conference Transcript - GuruFocus
- 2 days ago - Teva Pharmaceutical Industries Limited (TEVA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 3 days ago - Israel Has Been Mired In Controversy During Its War With Hamas. Big Tech Investment Tells A Different Story. - Investor's Business Daily
- 4 days ago - TEVA Forecasts Significant Rise in Cash Flow by 2030 - GuruFocus
- 5 days ago - Noteworthy ETF Inflows: IEFA, SPOT, SE, TEVA - Nasdaq
- 7 days ago - 30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks - The Motley Fool